Pubblicazioni scientifiche
Le pubblicazione realizzate dal 2022 in poi.
I progetti di ricerca e il sostegno alla divulgazione
Promuoviamo la corretta informazione, la divulgazione scientifica, la prevenzione e la raccolta fondi attraverso attività ed eventi sportivi e sociali.
I risultati più significativi delle ricerche sostenute in questi anni da Cancersucks sono stati pubblicati sulle più importanti riviste scientifiche. La divulgazione degli studi e delle scoperte in campo medico è indispendabile per consentire la diffusione
di nuove modalità di prevenzione, cura e stili di vita.
Sosteniamo i progressi della rierca
La diffusione di ogni nuova scoperta è funzionale al progredire della scienza. Se i ricercatori nel corso del loro lavoro ottengono risultati attendibili, l’articolo che descrive i metodi e le procedure, viene pubblicato su una rivista per consentire anche ad altri ricercatori di consultarle nei propri studi.
L’obiettivo è che tali risultati abbiano delle ricadute concrete e importanti nelle cure ai pazienti.
Nella foto: la Prof. Roberta Rudà, Direttore Divisione di Neuro-Oncologia, Dipartimento di Neuroscienze, Università e AOU Città della Salute e della Scienza di Torino (Molinette), e il Prof. Riccardo Soffietti, Dipartimento di Neuroscienze, Università di Torino.
2025
Karschnia P, Young JS, Wijnenga MMJ, Sciortino T, Teske N, Corell A, Wagner A, Youssef G, Park YW, Häni L, Jünger ST, Dono A, Ehret F, Mireles EEM, Neidert N, Bruno F, Tuchek CA, van der Vaart T, Rossi M, Nibali MC, Gay L, Gramelt A, Tandon N, Ahn SS, Chang JH, Weller M, Vincent AJPE, Goldbrunner R, Cahill DP, Huang RY, Raabe A, Meyer B, Beck J, Molinaro AM, Chang SM, Vogelbaum MA, Rudà R, Vik-Mo EO, Dietrich J, Esquenazi Y, Grau SJ, Wen PY, Jakola AS, Schnell O, Bello L, van den Bent MJ, Hervey-Jumper S, Berger MS, Tonn JC. A prognostic classification system for extent of resection in IDH-mutant grade 2 glioma: an international, multicentre, retrospective cohort study with external validation by the RANO resect group. Lancet Oncol. 2025 Dec;26(12):1638-1650. doi: 10.1016/S1470-2045(25)00534-0. PMID: 41308678. [IF: 35.9].
Rudà R, Bruno F, Pellerino A, Pronello E, Zotta M, Morbelli S. Early seizure freedom with [18F]fluorodopa positron emission tomography response after isocitrate dehydrogenase inhibition with vorasidenib: First case report. Epilepsia. 2025 Oct;66(10):e242-e247. doi: 10.1111/epi.18593. Epub 2025 Aug 6. PMID: 40956046; PMCID: PMC12605814.
Pascuzzo R, Rudà R, Barker PB, Xiang J, Antelmi L, Gianeri R, Pellerino A, Mo F, Soffietti R, Bizzi A. Glutamate to GABA ratio is elevated in patients with IDH-mutant lower-grade gliomas and seizures. Neurooncol Adv. 2025 Aug 20;7(1):vdaf155. doi: 10.1093/noajnl/vdaf155. PMID: 40893414; PMCID: PMC12391666.
Pellerino A, Priego N, Bertero L, Ricci AA, Mangherini L, Bruno F, Beano A, Mittica G, Mistrangelo M, Garbossa D, Bosch-Barrera J, Cassoni P, Renacer, Valiente M, Soffietti R, Rudà R. STAT3 expression in brain metastases from breast cancer is correlated with molecular subtype and impacts clinical outcome. Neuro Oncol. 2025 Aug 9:noaf187. doi: 10.1093/neuonc/noaf187. Epub ahead of print. PMID: 40795951. [IF: 15.9].
Galldiks N, Lohmann P, Aboian M, Barajas RF Jr, Breen WG, Ivanidze J, Johnson DR, Kaufmann TJ, Kim MM, Mair MJ, Minniti G, Müther M, Nabavizadeh A, Palmer JD, Rudà R, Smits M, Tolboom N, Veldhuijzen van Zanten SEM, Veronesi MC, Werner JM, van den Bent M, Chang SM, Langen KJ, Law I, McConathy J, Mehta M, Preusser M, Short SC, Soffietti R, Vogelbaum M, Weller M, Wen PY, Tonn JC, Albert NL. Update to the RANO working group and EANO recommendations for the clinical use of PET imaging in gliomas. Lancet Oncol. 2025 Aug;26(8):e436-e447. doi: 10.1016/S1470-2045(25)00193-7. PMID: 40744043. [IF: 35.9].
Rudà R, Bruno F, Pellerino A, Pronello E, Soffietti R. Low-grade IDH-mutant gliomas: from standard post-surgical treatments to novel IDH inhibitors. Expert Opin Pharmacother. 2025 Jul;26(10):1163-1175. doi: 10.1080/14656566.2025.2516617. Epub 2025 Jun 6. PMID: 40479721. [IF: 2.5].
de la Fuente MI, Touat M, van den Bent MJ, Preusser M, Peters KB, Young RJ, Huang RY, Ellingson BM, Capper D, Phillips JJ, Halasz LM, Shih HA, Rudà R, Lim-Fat MJ, Blumenthal DT, Weller M, Arakawa Y, Whittle JR, Ducray F, Reardon DA, Bi WL, Minniti G, Rahman R, Hervey-Jumper S, Chang SM, Wen PY. The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma. Neuro Oncol. 2025 Jun 21;27(5):1135-1148. doi: 10.1093/neuonc/noae259. Erratum in: Neuro Oncol. 2025 Feb 19:noaf032. doi: 10.1093/neuonc/noaf032. PMID: 39723472; PMCID: PMC12187374. [IF: 16.4].: 15.9].
Gallotti AL, Rossi M, Conti Nibali M, Sciortino T, Gay LG, Puglisi G, Leonetti A, Bruno F, Rudà R, Soffietti R, Cerri G, Bello L. Neuro-oncological superiority of supratotal resection in lower-grade gliomas. Neuro Oncol. 2025 Jun 21;27(5):1270-1284. doi: 10.1093/neuonc/noae264. PMID: 39657577; PMCID: PMC12187370. [IF: 16.4].
Ozair A, Wilding H, Bhanja D, Mikolajewicz N, Glantz M, Grossman SA, Sahgal A, Le Rhun E, Weller M, Weiss T, Batchelor TT, Wen PY, Haas-Kogan DA, Khasraw M, Rudà R, Soffietti R, Vollmuth P, Subbiah V, Bettegowda C, Pham LC, Woodworth GF, Ahluwalia MS, Mansouri A. Leptomeningeal metastatic disease: new frontiers and future directions. Nat Rev Clin Oncol. 2025 Feb;22(2):134-154. doi: 10.1038/s41571-024-00970-3. Epub 2024 Dec 9. PMID: 39653782. [IF: 81.1].
Priego N, de Pablos-Aragoneses A, Perea-García M, Pieri V, Hernández-Oliver C, Álvaro-Espinosa L, Rojas A, Sánchez O, Steindl A, Caleiras E, García F, García-Martín S, Graña-Castro O, García-Mulero S, Serrano D, Velasco-Beltrán P, Jiménez-Lasheras B, Egia-Mendikute L, Rupp L, Stammberger A, Meinhardt M, Chaachou-Charradi A, Martínez-Saez E, Bertero L, Cassoni P, Mangherini L, Pellerino A, Rudà R, Soffietti R, Al-Shahrour F, Saftig P, Sanz-Pamplona R, Schmitz M, Crocker SJ, Calvo A, Palazón A; RENACER; Valiente M. TIMP1 Mediates Astrocyte-Dependent Local Immunosuppression in Brain Metastasis Acting on Infiltrating CD8+ T Cells. Cancer Discov. 2025 Jan 13;15(1):179-201. doi: 10.1158/2159-8290.CD-24-0134. PMID: 39354883; PMCID: PMC11726018. [IF: 30.6].: 15.9].
2024
de la Fuente MI, Touat M, van den Bent MJ, Preusser M, Peters KB, Young RJ, Huang RY, Ellingson BM, Capper D, Phillips JJ, Halasz LM, Shih HA, Rudà R, Lim-Fat MJ, Blumenthal DT, Weller M, Arakawa Y, Whittle JR, Ducray F, Reardon DA, Bi WL, Minniti G, Rahman R, Hervey-Jumper S, Chang SM, Wen PY. The role of vorasidenib in the treatment of isocitrate dehydrogenase-mutant glioma. Neuro Oncol. 2024 Dec 25:noae259. doi: 10.1093/neuonc/noae259. Epub ahead of print. Erratum in: Neuro Oncol. 2025 Feb 19:noaf032. doi: 10.1093/neuonc/noaf032. PMID: 39723472. [IF: 16.4].
Panico F, Bianconi A, Bertero L, Palmiero R, Zeppa P, Ricci AA, Mangherini L, Cofano F, Rudà R, Garbossa D, Zenga F. Multidisciplinary treatment of a rare rapidly progressive intracranial myxoid mesenchymal tumor of uncertain differentiation FET-CREB fusion-negative. Neurol Sci. 2024 Dec 14. doi: 10.1007/s10072-024-07907-9. Epub ahead of print. PMID: 39673042. [IF: 2.7].
Gallotti AL, Rossi M, Conti Nibali M, Sciortino T, Gay LG, Puglisi G, Leonetti A, Bruno F, Rudà R, Soffietti R, Cerri G, Bello L. Neuro-Oncological Superiority of Supratotal Resection in Lower-Grade Gliomas. Neuro Oncol. 2024 Dec 7:noae264. doi: 10.1093/neuonc/noae264. Epub ahead of print. PMID: 39657577. [IF: 16.4].
Rudà R, Pellerino A, Soffietti R. Blood and cerebrospinal fluid biomarkers in neuro-oncology. Curr Opin Neurol. 2024 Dec 1;37(6):693-701. doi: 10.1097/WCO.0000000000001317. Epub 2024 Sep 27. PMID: 39329301. [IF: 4.1].
Karschnia P, Young JS, Youssef GC, Dono A, Häni L, Sciortino T, Bruno F, Juenger ST, Teske N, Dietrich J, Weller M, Vogelbaum MA, van den Bent M, Beck J, Thon N, Gerritsen JKW, Hervey-Jumper S, Cahill DP, Chang SM, Rudà R, Bello L, Schnell O, Esquenazi Y, Ruge MI, Grau SJ, Huang RY, Wen PY, Berger MS, Molinaro AM, Tonn JC; RANO resect group. Development and validation of a clinical risk model for postoperative outcome in newly diagnosed glioblastoma: a report of the RANO resect group. Neuro Oncol. 2024 Nov 4:noae231. doi: 10.1093/neuonc/noae231. Epub ahead of print. PMID: 39492786. [IF: 16.4].
Bianconi A, Presta R, La Cava P, De Marco R, Zeppa P, Lacroce P, Castaldo M, Bruno F, Pellerino A, Rudà R, Melcarne A, Garbossa D, Bo M, Cofano F. A novel scoring system proposal to guide surgical treatment indications for high grade gliomas in elderly patients: DAK-75. Neurosurg Rev. 2024 Oct 25;47(1):823. doi: 10.1007/s10143-024-03052-1. PMID: 39453521. [IF: 2.5].
Wilcox JA, Chukwueke UN, Ahn MJ, Aizer AA, Bale TA, Brandsma D, Brastianos PK, Chang S, Daras M, Forsyth P, Garzia L, Glantz M, Oliva ICG, Kumthekar P, Le Rhun E, Nagpal S, O’Brien B, Pentsova E, Lee EQ, Remsik J, Rudà R, Smalley I, Taylor MD, Weller M, Wefel J, Yang JT, Young RJ, Wen PY, Boire AA. Leptomeningeal metastases from solid tumors: A Society for Neuro-Oncology and American Society of Clinical Oncology consensus review on clinical management and future directions. Neuro Oncol. 2024 Oct 3;26(10):1781-1804. doi:10.1093/neuonc/noae103. PMID: 38902944; PMCID: PMC11449070. [IF: 16.4].
Boele F, Rosenlund L, Nordentoft S, Melhuish S, Nicklin E, Rydén I, Williamson A, Donders-Kamphuis M, Preusser M, Le Rhun E, Kiesel B, Minniti G, Furtner J, Dirven L, Taphoorn M, Galldiks N, Rudà R, Chalmers A, Short SC, Piil K. Inequalities in access to neuro-oncology supportive care and rehabilitation: A survey of healthcare professionals’ perspectives. Neurooncol Pract. 2024 Mar 15;11(4):484-493. doi: 10.1093/nop/npae023. PMID: 39006521; PMCID: PMC11241368. [IF: 2.7].
Galldiks N, Kaufmann TJ, Vollmuth P, Lohmann P, Smits M, Veronesi MC, Langen KJ, Rudà R, Albert NL, Hattingen E, Law I, Hutterer M, Soffietti R, Vogelbaum MA, Wen PY, Weller M, Tonn JC. Challenges, limitations, and pitfalls of PET and advanced MRI in patients with brain tumors: A report of the PET/RANO group. Neuro Oncol. 2024 Jul 5;26(7):1181-1194. doi: 10.1093/neuonc/noae049. PMID:38466087; PMCID: PMC11226881. [IF: 16.4].
Rudà R, Horbinski C, van den Bent M, Preusser M, Soffietti R. IDH inhibition in gliomas: from preclinical models to clinical trials. Nat Rev Neurol. 2024 Jul;20(7):395-407. doi: 10.1038/s41582-024-00967-7. Epub 2024 May 17. PMID: 38760442. [IF: 28.2].
Pellerino A, Davidson TM, Bellur SS, Ahluwalia MS, Tawbi H, Rudà R, Soffietti R. Prevention of Brain Metastases: A New Frontier. Cancers (Basel). 2024 Jun 4;16(11):2134. doi: 10.3390/cancers16112134. PMID: 38893253; PMCID: PMC11171378. [IF: 4.5].
Nayak L, Bettegowda C, Scherer F, Galldiks N, Ahluwalia M, Baraniskin A, von Baumgarten L, Bromberg JEC, Ferreri AJM, Grommes C, Hoang-Xuan K, Kühn J, Rubenstein JL, Rudà R, Weller M, Chang SM, van den Bent MJ, Wen PY, Soffietti R. Liquid biopsy for improving diagnosis and monitoring of CNS lymphomas: A RANO review. Neuro Oncol. 2024 Jun 3;26(6):993-1011. doi: 10.1093/neuonc/noae032. PMID: 38598668; PMCID: PMC11145457. [IF: 16.4].
Franchino F, Morra I, Forni M, Bertero L, Zanini C, Roveta F, Ricardi U, Mantovani C, Carpaneto A, Migliore E, Pellerino A, Ferrio F, Cassoni P, Garbossa D, Soffietti R, Rudà R. Medulloblastoma in adults: an analysis of clinico-pathological, molecular and treatment factors. J Neurosurg Sci. 2024 Jun;68(3):260-269. doi: 10.23736/S0390-5616.21.05548-X. Epub 2021 Nov 11. PMID:34763393. [IF: 2.392].
Bruno F, Pellerino A, Conti Nibali M, Pronello E, Cofano F, Rossi M, Levis M, Bertero L, Soffietti R, Cassoni P, Garbossa D, Bello L, Rudà R. Association of Clinical, Tumor, and Treatment Characteristics With Seizure Control in Patients With IDH1/2-Mutant Lower-Grade Glioma. Neurology. 2024 May;102(10):e209352. doi: 10.1212/WNL.0000000000209352. Epub 2024 Apr 29. PMID:38684041. [IF: 8.4].
Cofano F, Bianconi A, De Marco R, Consoli E, Zeppa P, Bruno F, Pellerino A, Panico F, Salvati LF, Rizzo F, Morello A, Rudà R, Morana G, Melcarne A, Garbossa D. The Impact of Lateral Ventricular Opening in the Resection of Newly Diagnosed High-Grade Gliomas: A Single Center Experience. Cancers (Basel). 2024 Apr 19;16(8):1574. doi: 10.3390/cancers16081574. PMID: 38672655; PMCID: PMC11049264. [IF: 4.5].
Karschnia P, Dono A, Young JS, Juenger ST, Teske N, Häni L, Sciortino T, Mau CY, Bruno F, Nunez L, Morshed RA, Haddad AF, Weller M, van den Bent M, Thon N,Beck J, Hervey-Jumper S, Molinaro AM, Tandon N, Rudà R, Vogelbaum MA, Bello L, Schnell O, Grau SJ, Chang SM, Berger MS, Esquenazi Y, Tonn JC. Associations between recurrence patterns and outcome in glioblastoma patients undergoing re-resection: A complementary report of the RANO resect group. Neuro Oncol. 2024 Mar 4;26(3):584-586. doi: 10.1093/neuonc/noad237. PMID: 38164632; PMCID:PMC10911992. [IF: 16.4].
Le Rhun E, Boele F, Minniti G, Galldiks N, Taphoorn M, Piil K, Rudà R, Niclou SP, Geurts M, Preusser M, Weller M, Short SC, Dirven L. Gender balance and suitable positive actions to promote gender equality among healthcare professionals in neuro-oncology: The EANO positive action initiative. Neurooncol Pract. 2023 Oct 3;11(1):46-55. doi: 10.1093/nop/npad064. PMID: 38222048; PMCID: PMC10785600. [IF: 2.4].
Avila EK, Tobochnik S, Inati SK, Koekkoek JAF, McKhann GM, Riviello JJ, Rudà R, Schiff D, Tatum WO, Templer JW, Weller M, Wen PY. Brain tumor-related epilepsy management: A Society for Neuro-oncology (SNO) consensus review on current management. Neuro Oncol. 2024 Jan 5;26(1):7-24. doi:10.1093/neuonc/noad154. PMID: 37699031; PMCID: PMC10768995. [IF: 16.4].
Karschnia P, Dietrich J, Bruno F, Dono A, Juenger ST, Teske N, Young JS, Sciortino T, Häni L, van den Bent M, Weller M, Vogelbaum MA, Morshed RA, Haddad AF, Molinaro AM, Tandon N, Beck J, Schnell O, Bello L, Hervey-Jumper S, Thon N, Grau SJ, Esquenazi Y, Rudà R, Chang SM, Berger MS, Cahill DP, Tonn JC. Surgical management and outcome of newly diagnosed glioblastoma without contrast enhancement (low-grade appearance): a report of the RANO resect group. Neuro Oncol. 2024 Jan 5;26(1):166-177. doi: 10.1093/neuonc/noad160. PMID: 37665776; PMCID: PMC10768992. [IF: 16.4].
Albert NL, Galldiks N, Ellingson BM, van den Bent MJ, Chang SM, Cicone F, de Groot J, Koh ES, Law I, Le Rhun E, Mair MJ, Minniti G, Rudà R, Scott AM, Short SC, Smits M, Suchorska B, Tolboom N, Traub-Weidinger T, Tonn JC, Verger A, Weller M, Wen PY, Preusser M. PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0): a report of the RANO group. Lancet Oncol. 2024 Jan;25(1):e29-e41. doi: 10.1016/S1470-2045(23)00525-9. PMID: 38181810. [IF: 41.6].
Pellerino A, Bertero L, Pronello E, Rudà R, Soffietti R. The early recognition and diagnosis of neoplastic meningitis. Expert Rev Neurother. 2024 Jan-Jun;24(1):105-116. doi: 10.1080/14737175.2023.2295999. Epub 2024 Jan 8. PMID: 38145502. [IF: 3.4].
2023
Rudà R, Capper D, Waldman AD, Pallud J, Minniti G, Kaley TJ, Bouffet E, Tabatabai G, Aronica E, Jakola AS, Pfister SM, Schiff D, Lassman AB, Solomon DA, Soffietti R, Weller M, Preusser M, Idbaih A, Wen PY, van den Bent MJ. EANO – EURACAN – SNO Guidelines on circumscribed astrocytic gliomas, glioneuronal, and neuronal tumors. Neuro Oncology. 2022 Dec 1;24(12):2015-2034. doi: 10.1093/neuonc/noac188. PMID: 35908833; PMCID: PMC9713532. [IF: 15.9].
Soffietti R, Pellerino A, Bruno F, Mauro A, Rudà R. Neurotoxicity from Old and New Radiation Treatments for Brain Tumors. International Journal of Molecular Sciences. 2023 Jun 26;24(13):10669. doi: 10.3390/ijms241310669. PMID: 37445846; PMCID: PMC10342178. [IF:5.6]
Hoang-Xuan K, Deckert M, Ferreri AJM, Furtner J, Gallego Perez-Larraya J, Henriksson R, Hottinger AF, Kasenda B, Lefranc F, Lossos A, McBain C, Preusser M, Roth P, Rudà R, Schlegel U, Soffietti R, Soussain C, Taphoorn MJB, Touitou V, Weller M, Bromberg JEC. European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL). Neuro-Oncology 2023 Jan 5;25(1):37-53. doi: 10.1093/neuonc/noac196. PMID: 35953526; PMCID:PMC9825335. [IF: 15.9].
Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F, Umemura Y, Nabors B, Holdhoff M, Hottinger AF, Arakawa Y, Sepulveda JM, Wick W, Soffietti R, Perry JR, Giglio P, de la Fuente M, Maher EA, Schoenfeld S, Zhao D, Pandya SS, Steelman L, Hassan I, Wen PY, Cloughesy TF; INDIGO Trial Investigators. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. New England Journal of Medicine. 2023 Aug 17;389(7):589-601. doi: 10.1056/NEJMoa2304194. Epub 2023 Jun 4. PMID: 37272516. [IF: 158.5].
Hertler C, Felsberg J, Gramatzki D, Le Rhun E, Clarke J, Soffietti R, Wick W, Chinot O, Ducray F, Roth P, McDonald K, Hau P, Hottinger AF, Reijneveld J, Schnell O, Marosi C, Glantz M, Darlix A, Lombardi G, Krex D, Glas M, Reardon DA, van den Bent M, Lefranc F, Herrlinger U, Razis E, Carpentier AF, Phillips S, Rudà R, Wick A, Tabouret E, Meyronet D, Maurage CA, Rushing E, Rapkins R, Bumes E, Hegi M, Weyerbrock A, Aregawi D, Gonzalez-Gomez C, Pellerino A, Klein M, Preusser M, Bendszus M, Golfinopoulos V, von Deimling A, Gorlia T, Wen PY, Reifenberger G, Weller M. Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419). European Journal of Cancer. 2023 Aug;189:112913. doi:10.1016/j.ejca.2023.05.002. Epub 2023 May 8. PMID: 37277265. [IF: 8.4].
Rudà R, Bruno F, Pellerino A. Epilepsy in gliomas: recent insights into risk factors and molecular pathways. Current Opinion in Neurology. 2023 Dec 1;36(6):557-563. doi:10.1097/WCO.0000000000001214. Epub 2023 Sep 29. PMID: 37865836. [IF: 5.4].
Picca A, Bruno F, Nichelli L, Sanson M, Rudà R. Advances in molecular and imaging biomarkers in lower-grade gliomas. Expert Review in Neurotherapeutics. 2023 Jul-Dec;23(12):1217-1231. doi: 10.1080/14737175.2023.2285472. Epub 2023 Dec 15. PMID: 37982735. [IF: 4.3].
Pellerino A, Bruno F, Soffietti R, Rudà R. Antiangiogenic Therapy for Malignant Brain Tumors: Does It Still Matter? Current Oncology Reports. 2023 Jul;25(7):777-785. doi: 10.1007/s11912-023-01417-1. Epub 2023 Apr 18. PMID: 37071295; PMCID: PMC10256654. [IF: 4.7].
Capper D, Reifenberger G, French PJ, Schweizer L, Weller M, Touat M, Niclou SP, Euskirchen P, Haberler C, Hegi ME, Brandner S, Le Rhun E, Rudà R, Sanson M, Tabatabai G, Sahm F, Wen PY, Wesseling P, Preusser M, van den Bent MJ. EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection. Neuro-Oncology. 2023 May 4;25(5):813-826. doi: 10.1093/neuonc/noad008. PMID: 36632791; PMCID:PMC10158123. [IF: 15.9]
Karschnia P, Young JS, Dono A, Häni L, Sciortino T, Bruno F, Juenger ST, Teske N, Morshed RA, Haddad AF, Zhang Y, Stoecklein S, Weller M, Vogelbaum MA, Beck J, Tandon N, Hervey-Jumper S, Molinaro AM, Rudà R, Bello L, Schnell O, Esquenazi Y, Ruge MI, Grau SJ, Berger MS, Chang SM, van den Bent M, Tonn JC. Prognostic validation of a new classification system for extent of resection in glioblastoma: A report of the RANO resect group. Neuro-Oncology. 2023 May 4;25(5):940-954. doi: 10.1093/neuonc/noac193. PMID: 35961053; PMCID: PMC10158281. [IF: 15.9].
Rudà R. Optimize treatment approaches in isocitrate dehydrogenase (IDH) mutant gliomas: open issues. Neuro-Oncology. 2023 Jan 5;25(1):26-27. doi:10.1093/neuonc/noac227. PMID: 36245275; PMCID: PMC9825343. [IF: 15.9].
2022
Soffietti R, Bettegowda C, Mellinghoff IK, Warren KE, Ahluwalia MS, De Groot JF, Galanis E, Gilbert MR, Jaeckle KA, Le Rhun E, Rudà R, Seoane J, Thon N, Umemura Y, Weller M, van den Bent MJ, Vogelbaum MA, Chang SM, Wen PY. Liquid biopsy in gliomas: A RANO review and proposals for clinical applications. Neuro Oncol. 2022 Jun 1;24(6):855-871. doi:10.1093/neuonc/noac004. PMID: 34999836; PMCID: PMC9159432. [IF: 12.300].
Rudà R, Bruno F, Ius T, Silvani A, Minniti G, Pace A, Lombardi G, Bertero L, Pizzolitto S, Pollo B, Conti Nibali M, Pellerino A, Migliore E, Skrap M, Bello L, Soffietti R. IDH wild-type grade 2 diffuse astrocytomas: prognostic factors and impact of treatments within molecular subgroups. Neuro Oncol. 2022 May 4;24(5):809-820. doi:10.1093/neuonc/noab239. PMID: 34651653; PMCID: PMC9071340. [IF: 12.300].
Bruno F, Pellerino A, Palmiero R, Bertero L, Mantovani C, Garbossa D, Soffietti R, Rudà R. Glioblastoma in the Elderly: Review of Molecular and Therapeutic Aspects. Biomedicines. 2022 Mar 10;10(3):644. doi:10.3390/biomedicines10030644. PMID: 35327445; PMCID: PMC8945166. [IF: 6.081].
Pellerino A, Soffietti R, Bruno F, Manna R, Muscolino E, Botta P, Palmiero R, Rudà R. Neratinib and Capecitabine for the Treatment of Leptomeningeal Metastases from HER2-Positive Breast Cancer: A Series in the Setting of a Compassionate Program. Cancers (Basel). 2022 Feb 25;14(5):1192. doi:10.3390/cancers14051192. PMID: 35267501; PMCID: PMC8909342. [IF: 6.126].